M
Michael R. Zile
Researcher at Medical University of South Carolina
Publications - 69
Citations - 8044
Michael R. Zile is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 28, co-authored 64 publications receiving 6145 citations. Previous affiliations of Michael R. Zile include Sewanee: The University of the South & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Abstr Act +11 more
TL;DR: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
Journal ArticleDOI
Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction
Michael R. Zile,John S. Gottdiener,Scott Hetzel,John J.V. McMurray,Michel Komajda,Robert S. McKelvie,Catalin F. Baicu,Barry M. Massie,Peter E. Carson +8 more
TL;DR: Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF, and left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality.
Journal ArticleDOI
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D. Solomon,Muthiah Vaduganathan,Brian Claggett,Milton Packer,Milton Packer,Michael R. Zile,Michael R. Zile,Karl Swedberg,Karl Swedberg,Jean L. Rouleau,Marc A. Pfeffer,Akshay S. Desai,Lars Lund,Lars Køber,Inder S. Anand,Nancy K. Sweitzer,Gerard C.M. Linssen,Béla Merkely,Juan Luis Arango,Dragos Vinereanu,Chen Huan Chen,Michele Senni,Antonio S. Sibulo,Sergey Boytsov,Victor Shi,Adel R. Rizkala,Martin Lefkowitz,John J.V. McMurray +27 more
TL;DR: The therapeutic effects of sacubitril/valsartan, compared with a renin-angiotensin-aldosterone–system inhibitor alone, vary by LVEF with treatment benefits, particularly for heart failure hospitalization, that appear to extend to patients with heart failure and mildly reduced ejection fraction.
Journal ArticleDOI
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
Scott D. Solomon,Adel R. Rizkala,Jianjian Gong,Wenyan Wang,Inder S. Anand,J.B. Ge,Carolyn S.P. Lam,Aldo P. Maggioni,Felipe Martinez,Milton Packer,Marc A. Pfeffer,Burkert Pieske,Margaret M. Redfield,Jean L. Rouleau,Dirk J. van Veldhuisen,Faiez Zannad,Michael R. Zile,Michael R. Zile,Akshay S. Desai,Victor Shi,Martin Lefkowitz,John J.V. McMurray +21 more
TL;DR: The PARAGON-HF trial will determine whether sacubitril/valsartan is superior to angiotensin receptor blockade alone in patients with chronic symptomatic HFpEF.
Journal ArticleDOI
A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS
Michael J. Domanski,Heidi Krause-Steinrauf,Barry M. Massie,Prakash Deedwania,Dean Follmann,David Kovar,David R. Murray,Ron M. Oren,Yves Rosenberg,James B. Young,Michael R. Zile,Eric J. Eichhorn +11 more
TL;DR: The possibility that different heart failure population subgroups may have different responses to beta-blocker therapy is suggested, which is related to differences in the clinical and demographic characteristics of the study populations.